MetaCap

Savara Inc. (SVRA)

NASDAQ: SVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.26-0.95 (-18.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SVRA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$939.86M
EPS (TTM)
-$0.60
52-week range
4.00 – 7.01
Day range
4.00 – 4.52
Volume / Avg
17.01M / 2.79M
Beta
—

52-week range

$4.00$7.01

SVRA stock today

On Nov 20, SVRA ended the session at $4.26, shedding $0.95 (18.23%), versus the S&P 500's 3.70% decline. Volume was 6.1x the average at 17.01M shares, a sign of unusually heavy trading. At this level, SVRA sits near the bottom of its 52-week range of $4.00 to $7.01: 39.2% below the high, set on Dec 12, 2025 and 6.5% above the low.

SVRA is down 29.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.4%. Savara has posted a net loss over the last twelve months (EPS of -$0.60), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Savara

Company profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Matthew Pauls J.D., M.B.A.
Headquarters
Yardley, PA
Employees
70

Financial highlights

Full financials

Savara reported a net loss of $118.8 million, compared with a loss of $95.9 million a year earlier. Diluted earnings per share came in at -$0.53.

Savara annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-118.84M$-95.88M$-54.70M$-38.15M$-43.01M
EPS (diluted)$-0.53$-0.48$-0.33$-0.25$-0.32

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$11.06+159.62%

  • Strong buy 3
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $16.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.17 vs $-0.18
Surprise
+5.56%

SVRA news

All SVRA news

Savara peers

Health Care sector
SVRA peer companies
CompanyPrice% ChgMarket capCompare
MLTXMoonLake Immunotherapeutics Class A11.07+0.36%$942.13Mvs SVRA
CYRXCryoPort Inc.19.05-2.56%$964.87Mvs SVRA
SPTXSeaport Therapeutics Inc.18.05-1.47%$966.23Mvs SVRA
AKTSAktis Oncology Inc.16.15-1.52%$901.14Mvs SVRA
OMEROmeros Corporation13.21-5.71%$983.66Mvs SVRA
ANROAlto Neuroscience Inc.25.37-4.30%$1.02Bvs SVRA
LTGOLatigo Biotherapeutics Inc.13.00-1.81%$861.89Mvs SVRA
MTRIMentari Therapeutics Inc.14.70-3.57%$856.94Mvs SVRA

Indexes, lists and sector

Savara stock FAQ

What is Savara's stock price today?

SVRA last traded at $4.26 as of Nov 20, 4:00 PM EST, down 18.23% on the day. Prices are delayed at least 15 minutes.

Who is Savara's CEO?

Mr. Matthew Pauls J.D., M.B.A. is the chief executive officer of Savara Inc., which has about 70 employees.

What is the SVRA 52-week high?

The 52-week high for SVRA is $7.01 and the 52-week low is $4.00. The stock is currently 39.2% below its high.

Compare SVRA